Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancersChad A. Hamilton, John K. Chan|British Journal of Cancer|2006Cited by 658
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Melissa A. Geller et al.|The Lancet Oncology|2019Cited by 533
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K. Chan, Bradley J. Monk|New England Journal of Medicine|2016Cited by 365